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Available online 1 December 2015Human bonemarrow stromal cells (hBMSCs, also loosely called bonemarrow-derivedmesenchymal stem cells)
are the subject of increasing numbers of clinical trials and laboratory research. Our group recently reported on the
optimization of a workﬂow for a sensitive proteomic study of hBMSCs. Here, we couple this workﬂow with a
label-free protein quantitation method to investigate the molecular responses of hBMSCs to long-term in vitro
passaging. We explored the proteomic responses of hBMSCs by assessing the expression levels of proteins at
early passage (passage 3, P3) and late passage (P7). We used multiple biological as well as technical replicates
to ensure that the detected proteomic changes are repeatable between cultures and thus likely to be biologically
relevant. Over 1700 proteins were quantiﬁed at three passages and a list of differentially expressed proteins was
compiled. Bioinformatics-based network analysis and term enrichment revealed that metabolic pathways are
largely altered, where many proteins in the glycolytic, pentose phosphate, and TCA pathways were shown
to be largely upregulated in late passages. We also observed signiﬁcant proteomic alterations in functional
categories including apoptosis, and ER-based protein processing and sorting following in vitro cell aging. We
posit that the comprehensive map outlined in this report of affected phenotypes as well as the underpinning
molecular factors tremendously beneﬁt the effort to uncovering targets that are not just used only to
monitor cell ﬁtness but can be employed to slowdown the in vitro aging process in hBMSCs and hence ensure
manufacturing of cells with known quality, efﬁcacy and stability.
Published by Elsevier B.V.1. Background
Much of the recent attention paid to human bone marrow stromal
cells (hBMSCs) is a consequence of their promise in cell-based therapy
(Yi and Song, 2012). Features of BMSCs claimed that beneﬁcial may
include the capacity to home to sites of damage, differentiate into
mature cells of the mesenchymal lineages, and secrete or stimulate
the production of bioactive molecules. However, numerous studies
have shown that extensive engraftment of BMSCs occurs rarely and
thus they may act primarily through the release of soluble factors or
through cell–cell interactions (Bernardo et al., 2012; Devine et al.,
2003). Following their initial discovery in bone marrow, cells with
similar surface characteristics have been isolated from many postnatal
tissues (Otto andWright, 2011), and these cells share common proper-
ties such as the capacity to adhere to plastic in cell culture and expres-
sion of common marker proteins (e.g., CD73, CD90, and CD105) orechnology Branch, Division of
on and Research, US FDA, Silver
lterman).lack of other markers (e.g., CD11b, CD14, CD19, CD45, and HLA-DR)
(Dominici et al., 2006; Keating, 2012). In bone marrow, they are a rare
population (at times, from adult bone marrow only as few as 2000
BMSCs could be recovered) (Ksiazek, 2009). And yet, considerably
higher cell numbers are often required for effective laboratory research
or for clinical applications (106–109 cells per kg body weight (Wang
et al., 2011; Yi and Song, 2012)). Hence, to obtain BMSCs in sufﬁcient
quantity, extensive in vitro culturing of primary cells is often necessary.
In regard to long-term culturing, the optimization of protocols con-
tinues to be a work in progress. One key challenge is the decline in
cell ﬁtness with in vitro passaging and this may impact the therapeutic
beneﬁt of BMSCs. For example, while early passage BMSCs support the
expansion and differentiation of hematopoietic cells, the late passages
(passage nine and beyond) did not exhibit this property (Briquet
et al., 2010). Studies show that late passage BMSCs exhibit various
indices of aging including altered growth kinetics with subsequent pro-
liferation arrest, altered morphology and clonogenicity, diminished dif-
ferentiation capacity, increased levels of reactive oxygen species (ROS),
p21 and p53 (Bruder et al., 1997; Lo Surdo and Bauer, 2012; Lo Surdo
et al., 2013; Wagner et al., 2008). These changes could be the result of
reorganization at genomic, epigenetic, transcriptomic, and proteomic
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frequency, during passaging (4% in human BMSCs vs 9% in human
pluripotent stem cells (hPSCs)) (Ben-David et al., 2011). Some tran-
scriptome proﬁling experiments revealed that genes associated with
cell death and chromatin assembly were up-regulated while those re-
lated to cell cycle, DNA repair, and DNA metabolism were largely
down-regulated with in vitro aging (Bin Noh et al., 2010; Wagner
et al., 2008). Meanwhile, epigenetic studies suggest that DNA-
methylation changes better correlate with the in vitro cell aging
than other genetic changes (Redaelli et al., 2012; Schellenberg
et al., 2011).
Traditional 2D-gel based approaches have been applied to study var-
ious aspects of the BMSC proteome including differentiation-associated
changes (Kasper et al., 2009; Sun et al., 2006), alterations in BMSCs as a
result of disease (Seshi, 2006), changes initiated by mechanical stress
(Yi et al., 2010), and the changes associated with in vitro cell passaging
of BMSCs (Celebi and Elcin, 2009; Madeira et al., 2012). Taken together
with other related studies, proteomic analyses undoubtedly provide
important insights into the proteomic composition of BMSCs and help
evolve our understanding about their biology. Nonetheless, more
studies are needed, especially when many questions regarding the
determinants of cell growth and development in culture media
remain unanswered. In addition, molecular markers that correlate
with developmental stages of cells, which may be utilized to monitor
quality attributes of BMSCs, are yet to be revealed. Contemporary
proteomic techniques are better placed to satisfy higher demands
of characterizing complex biological systems than what could
be achieved a few years ago. Such techniques combine the use of
multidimensional chromatographic separation, high resolution
mass spectrometry (MS), and improved bioinformatic data handling
systems. The present work utilizes a workﬂow, which we recently
optimized to survey the proteomics of human BMSCs and investigate
the impact of long-term in vitro cultivation on protein expression
in BMSCs. Based on multiple replicates; we performed an in-depth
proteomic survey on hBMSCs at three passage stages (P3, P5 and P7).
We used a label-free protein quantiﬁcation technique to determine
protein abundance and changes in response to long-term passaging.
The technique uses the average intensity of the three most intense
tryptic peptides per mole of a protein as surrogate to estimate protein
abundance, a trend described by Silva et al. (2006). Our results provide
detailed molecular insights of those changes that follow long-term
in vitro cell passaging and offer potentially valuable protein targets for
further studies to identify molecular markers that may correlate with
hBMSC function.
2. Material and methods
2.1. Cell culture preparation
BMSCs from ﬁve human donors were purchased from commercially
available sources (described in Ref. Mindaye et al., submitted for
publication). According to the manufacturers, informed consent
was received from donors and all participants fulﬁlled institutional
requirements. Bone marrow aspirates were harvested and plastic
adherent BMSCs were expanded. The time in culture prior to harvest
was 15, 15, and 14 days for cultures 167696 (at 90% conﬂuence),
110877 (at 45% conﬂuence), and 8F3560 (at 35% conﬂuence), respec-
tively. At this stage, BMSCs were designated as passage zero (P0) by
the supplier. These three cultures were further cultured to P1 for 6, 6,
and 7 days, respectively, collected at 95% conﬂuence, and frozen. P0
cells from PCBM1632 and PCBM1662 were in culture up to 80%
conﬂuence for 15 and 20 days, respectively before collection at P1.
Results of the extensive characterization and authentication of all
BMSCs were reported in previous publications (Lo Surdo and Bauer,
2012; Lo Surdo et al., 2013;Mindaye et al., 2013a, 2013b). Cells conform
to speciﬁcations of the International Society for Cellular Therapy withregard to the expression of surface markers; namely, the expression of
positive markers (≥90% positive for CD29, CD44, CD105, and CD166)
and are negative for hematopoietic stem cell markers (Dominici et al.,
2006). We also showed that these cells were capable of in vitro
adipogenesis (Lo Surdo and Bauer, 2012; Lo Surdo et al., 2013).
P1 cells were plated at 60 cells/cm2 in T175 ﬂasks (Cellstar), culture-
expanded in α-MEM (Invitrogen) supplemented with 16.5% fetal
bovine serum (FBS) (JM Bioscience, San Diego, CA), L-glutamine
and penicillin–streptomycin (Pen/strep) (Invitrogen), and cultured at
37 °C and 5% CO2 as described earlier (Lo Surdo and Bauer, 2012; Lo
Surdo et al., 2013). At 80% conﬂuence, cells were harvested using
0.25% Trypsin/EDTA (Invitrogen), washed using phosphate buffered
saline three times, snap frozen in liquid nitrogen, and stored at−80 °C
at 5 × 106 cells at passages 3 (P3), 5 (P5), and 7 (P7) for later use. A pas-
sage number is thenumber of times cellswere trypsinized prior to freez-
ing. Respectively, the time to P3, P5, and P7 was: 167696 (8, 10, and 12
days), PCBM1632 (7, 9, and 17 days), 110877 (8, 9, and10days), 8F3560
(9, 10, 9 days), and PCBM1662 (10, 9, and 12 days). The same serum lot
was used to expand all cell cultures for all passages. The cultures vary in
their proliferation capacity, which generally decreases with passaging.
The full proliferation characterization was described in previous publi-
cations (Lo Surdo and Bauer, 2012; Lo Surdo et al., 2013; Mindaye
et al., 2013a).
2.2. Proteome preparation, nanoLC-MSE analysis, data processing, and
database searching
The detailed protocol for sample preparation, nanoLC-MSE acquisi-
tion, Protein LynxGlobal Surver (PLGS)-based data processing, database
searching, and additional bioinformatic analyses are provided else-
where (Mindaye et al., submitted for publication). Brieﬂy, hBMSCs
were lysed under SDS buffer conditions with the help of sonication
and alternating pressure using a Barocycler (Pressure Biosciences,
South Easton, MA). Cell lysates from culture 167696 and PCBM1632
were electrophoretically resolved into six fractions using the Gel-
Eluted Liquid Fraction Entrapment Electrophoresis (GELFREE) system
(Protein Discovery, Knoxville, TN) that allowed continuous separation
of proteins through a gel-packed tube. Eluting proteins are trapped by
amolecularweight cut-off membrane and subsequently collected in so-
lution phase, which was suitable for downstream nanoLC-MSE analysis.
From 200 μg of total protein, six fractions were collected (procedure
described in Ref. Mindaye et al., submitted for publication). Based on
polyacrylamide gel electrophoresis, the ﬁrst fraction was estimated to
contain ~40% of the total protein loaded and each of the subsequent
ﬁve fractions had ~12%. In the remaining three cell cultures the whole
cell lysate was trypsinized without prior GELFREE fractionation.We ex-
cluded the upfront protein fractionation step for multiple reasons. First,
the extra protein fractionation signiﬁcantly increased the analysis
time on the nanoLC-MSE part. Secondly, a signiﬁcantly higher protein
amount is needed for the GELFREE fractionation step to produce sufﬁ-
cient material for downstream analyses. Furthermore, during protein
fractionation, the migration of proteins through the gel is not necessar-
ily sharp and proteins tend to tail between adjacent 1D gel fractions. The
extent of such tailing varies between gel runs and thus might increase
the error incurred during quantitative protein analysis. For samples
processed without the protein fractionation step, we increased the
number of fractions on the nanoLC part (described in Ref. Mindaye
et al., submitted for publication).
The digest was eluted on a 2D nanoAcquity UPLC system with
subsequent data-independent MS analysis (MSE), which was carried
out using SynaptG2MS.MSE data acquisition involves alternating the
energy applied to the collision cell on a scan-by-scan basis without
using an ion transmission window. This modality of data acquisition
is expected to improve the overall depth of proteome coverage as it
enables collection of data on precursor as well as product ion on all iso-
topes and charge states across the entire chromatographic peak width.
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and the output was used to search against human SwissProt database.
The detailed steps of time-alignment, ion accounting, correlation of
precursor and product ion spectra, and database searching are de-
scribed elsewhere (Geromanos et al., 2009; Li et al., 2009). A one-time
randomized target database was used as decoy to calculate the false
discovery rate of protein identiﬁcation. Generally, the protein identiﬁ-
cation conﬁdence was high as most proteins were identiﬁed using
more than one peptide.
2.3. Label-free protein quantiﬁcation, conﬁrmation using ﬂow cytometry,
and bioinformatic analyses
The label-free protein quantiﬁcation workﬂow relies on the average
signal intensity of three most intense tryptic peptides per mole of a
protein, an observation noted previously (Silva et al., 2006). Using this
technique the relative concentration of proteins was determined
and proteins whose expression levels at P5 and P7 were signiﬁcantly
different compared to the level at P3 (two-tailed t-test, p value ≤0.05)
were identiﬁed. Further conﬁrmation of differential expression was
performed for some of the proteins using ﬂow cytometry as an
independent system. For this experiment, cells (cultures 167696
and PCBM1632) were thawed at either P3 or P7, cultured to 80% con-
ﬂuence, and incubated with 2.4G2 antibodies (ATCC) at 4 °C for
30 min to block non-speciﬁc binding. Then, ﬂuorochrome-labeled
antibodies (phycoerythrin [PE]; allophycocyanin [APC]; and ﬂuores-
cein thiocyanate [FITC]) were added to aliquots of cells. Data were
acquired using a FACS Canto II (BD Biosciences, San Jose, CA) ﬂow
cytometer and data analysis was completed using FlowJo Analysis
Software (Tree Star, Ashland, OR).
Subcellular location prediction for identiﬁed proteins was per-
formed using PANTHER server (Mi et al., 2013) and GProX was
used for clustering analysis (Rigbolt et al., 2011). Biological function,
protein network assignment, and other bioinformatic analyses were
performed using either the Ingenuity Pathway Analysis application
(IPA v9, Ingenuity Systems Inc., USA) or ArrayTrack data analysis and in-
terpretation tool (www.fda.gov/ScienceResearch/BioinformaticsTools/
Arraytrack). In IPA, Core Analyses were run using the focus protein
sets (differentially expressed proteins) togetherwith the corresponding
fold changes using the default set parameters. Networks and biological
functions were algorithmically generated and signiﬁcance of each
network and enriched functions was assessed using Fisher's exact test.
Furthermore, the activation z-score, which is a measure of regulation
of biological functions, was calculated based on experimentally
observed functional changes that are compiled in the Ingenuity
Knowledge Database (IKDB).
3. Results
3.1. The proteome of hBMSCs
In our previous reports, we established a robust workﬂow based on
complementary MS techniques and developed a database that is larger
than any database previously reported for hBMSC's proteome (Mindaye
et al., 2013a, 2013b). There, we highlighted the proteomic basis of
heterogeneity between cell cultures and identiﬁed proteins for which
there was no prior evidence of expression on hBMSCs. The primary
objective of the present study was to take advantage of the analytical
platform we optimized and the database we constructed to further
investigate the protein expression program in hBMSCs particularly
during long-term in vitro culturing. Proteomic screeningwas performed
at three passages (P3, P5, and P7). The dataset revealed at least 5000
proteins could be identiﬁed at each passage (see S1 and S1_Exp in
Mindaye et al., submitted for publication). The dynamic range of
proteins expressed in hBMSCs, as estimated using the average of
protein-matched peptide intensity sum in triplicate runs at P3, spans4 to 6 orders of magnitude (Fig. 1 in Mindaye et al., submitted for
publication). This shows the expression-level variation of individual
proteins in hBMSC. Structural proteins represent the major portion of
the total proteomic signal, where proteins such as actins, vimentin,
annexins, and histones alone accounted for over 50% of the total prote-
omic mass. Further, in order to assess the link between relative protein
abundance and biological functions, we divided the proteome at P3
(PCBM1662) into ﬁve quantiles (Q1 through Q5) based on the
estimated protein abundances. Bioinformatic gene ontology (GO)
followed by Fisher's exact test extracted the search terms in each
quantile, and terms with p b 0.02 are shown in Fig. 1. The most abun-
dant proteins enrich biological functions in Q1 and the least abun-
dant ones are represented by Q5. Proteins disulﬁde isomerase,
reticulon, and thioredoxin have near median abundance values
in Q1. Group Q2 can be exempliﬁed by proteins such as ATP-
dependent RNA helicase, HLA class I histocompatibility antigen,
and ribosomal proteins, while in Q3 eukaryotic translation factor,
basigin, and endophilin have near median estimated abundances.
Papilin, chromobox protein homolog, and DNA replication licensing
factor represent Q4, whereas transmembrane emp24 domain con-
taining protein and peptidyl prolyl transisomerase are examples of
proteins in Q5.
The enrichment shows the most abundant proteins in hBMSC are
either glycolytic or involved in translation in ribosomes, transcription
in spliceosomes, or have cellular communication functions through
focal adhesion, tight, and adherence junctions. Core biological functions
such as metabolism require proteins in a wider abundance range.
Carbohydrate and protein metabolism is mostly executed by proteins
in the moderate to higher abundance bracket, whereas metabolism
of fatty acids and vitamins requires proteins in lower abundance.
Functional categories involving protein folding, sorting, degradation,
and transport are executed by proteins with high abundance as well
as rare proteins. In addition, hBMSCs are thought to have an immuno-
modulatory role, and our analysis shows that proteins in the immune
system network (e.g., leukocyte trans-endothelial migration, antigen
processing and presentation) exist largely in higher abundance. It
should be noted that these enrichment results are based on relative
protein quantity estimation and primarily provides a general under-
standing as to how cell protein mass is allocated with regard to speciﬁc
biological functions. Largely, our ﬁndings are consistent with results
of similar studies that correlate protein abundance with biological
functions in other human cells (Beck et al., 2011).
In total, over 5000 proteins per passage were identiﬁed (Mindaye
et al., 2013a, and S1 in Mindaye et al., submitted for publication);
of which 3218 were identiﬁed in all three passages and 1865 were
identiﬁed only in either passage. From the 1865 proteins, 778 were
identiﬁed only at P3, 725 at P5, and 362 at P7. Proteins with passage-
dependent expression proﬁles were identiﬁed in fewer cell cultures
and this owes to their lower abundance in hBMSC proteome. Only 275
proteins (35%) of the P3-associated proteins could be identiﬁed from
three or more of the ﬁve cell sources. From the P5- and P7-speciﬁc
proteins, 39% and 36% of them, respectively, followed similar passage-
dependency in three or more occasions. Proteins mainly expressed in
late passages include tumor protein p53 inducible protein 3 (TP53I3);
an enzyme that is involved in cellular responses to oxidative stress.
TP53P3 has been identiﬁed at P7 from samples 167696, PCBM1632,
and PCBM1662 and could not be detected from the other cultures. The
gene that encodes TP53I3 contains a p53 binding site and is activated
by p53 and is involved in p53-mediated cell death and replicative senes-
cence (Voltan et al., 2014). The transcription factor SOX18 (SRY-related
HMG-box family) has also been identiﬁed only from passage P7 cells
from all samples except from 110877 (Mindaye et al., 2013a, and S1 in
Mindaye et al., submitted for publication). SOX18 is expressed innormal
tissue as well as in cancer cells and it has been implicated in numerous
biological processes including modulating stem cell proliferation, cell
fate determination, cell maturation, and angiogenesis (Hoeth et al.,
Fig. 1. GO enrichment based on protein abundance in hBMSCs (PCBM1662 at P3). The expression level of proteins was estimated using the average product ion intensity from triplicate
runs and the proteome was divided into ﬁve equal quantiles (Q1 through Q5). Fisher's exact test extracted GO terms for each quantile and those with a p value ≤ 0.02 are listed on top of
each quantile. These GO terms are represented by bars (from left to right) and the y-axes are the negative log of p values.
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also include DDX20 (an RNA helicase that is associated with gene
expression and induction of apoptosis), dual oxidase 1 (involved in
oxidative stress), tousled-like kinase 2, and others with less understood
biological functions.3.2. Quantitative survey of protein expression proﬁle in hBMSCs following
expansion
The label-free protein quantitation method adopted in this study
takes advantage of the linear relationship between MS signal response
and protein concentration (Silva et al., 2006). The average signal count
using three most intense tryptic peptides per mole of a protein corre-
sponds to constant MS signal response. Therefore, using a known quan-
tity of protein as an internal standard, the concentration of other
detectable proteins in a digest can be estimated. In order to assess the
suitability of this protein quantiﬁcation method for such complex sam-
ples as hBMSC lysate, we spiked bovine catalase and alcohol dehydroge-
nase (ALDH) at the molar ratio of 2.75:1 to the hBMSC digest. Multiple
runs of 2D nanoLC-MSE were acquired. The MS signal response ratios
of catalase and ALDH over multiple injections in separate days was
determined to be stable with an overall 16% coefﬁcient of variation
(Fig. 2 in Ref. Mindaye et al., submitted for publication). Furthermore,
as applied to the actual hBMSCs proteome, the run-to-run quantitative
repeatability was fairly robust as demonstrated in Fig. 3 of Mindaye
et al. (submitted for publication).S1 and S1_Exp in Ref. Mindaye et al. (submitted for publication)
summarize the identity and quantitative statistics of proteins identiﬁed
from the ﬁve samples. For each culture, equal amount of total protein
digest at P3, P5, and P7 was loaded onto a nanoLC column and the
quantity of individual proteinwas calculated using catalase as the inter-
nal standard. For comparative purposes, the protein content at P3 was
considered as the reference expression level, and thus a fold change is
the ratio of on-column protein contents between P3 and later passages.
In instances where low abundant proteins could be identiﬁed by less
than three peptides, the fold changes were estimated using the normal-
ized protein-matched peptide intensity sum. In this case, normalization
was performed using the total precursor ion intensity of the internal
standard (bovine catalase). There are also cases where proteins could
be identiﬁed and quantiﬁed at one passage but could not be detected
at others. Although failure to identify proteins at certain passages
is most likely a matter of expression level difference rather than an
on-or-off type of change, it is difﬁcult to assign fold changes for such
proteins. Thus, such proteins were not included in the differentially
regulated proteins list during further bioinformatic enrichment.
Unsupervised clustering was carried out using the average fold
changes of proteins at P5 and P7 (across ﬁve cultures). The GProX
software partitioned the expression trend into six distinct clusters as
shown in Fig. 3. The gene ontology search in KEGG database using
ArrayTrack identiﬁed the corresponding biological functions that repre-
sent each cluster and the top most functions are listed at the bottom of
each group. The clustering revealsmost proteins appear to have reduced
expression levels at P5 (Cluster 4 (112 proteins), C5 (161 proteins),
Fig. 2. Unsupervised clustering using GProX shows distinct protein expression patterns. The average fold changes on a log2 scale from ﬁve cultures (at P3, P5, and P7, where P3 is the
reference level) were used for clustering. Upper and lower log2 limits of 0.58 and−0.32, which correspond to a 1.5 and−1.25 fold change, respectively, were considered the cut-off
value.Membership value is themeasure of howwell a protein proﬁle resembles the average cluster proﬁle, where, a number close to one (yellow) indicates a proﬁle closer to the average
in the cluster.
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(expression at P3) when cells were further expanded to P7. Cluster 4
shows proteins whose content returned to the level similar to P3 and
C6 has proteins expressed even at slightly higher level at P7 compared
to P3. Cluster 5 represents the expression trend that remained lower at
P7 as compared to P3. Similarly, clusters 1–3 represent proteins with
an overall upward expression trend.
3.3. The expression of proteins in metabolic networks
One of the systematic changes identiﬁed by GO enrichment in
KEGG database relates to the metabolic networks. Pathways including
glycolysis, pentose phosphate pathway, pyruvate metabolism, and
the citrate cycle all seem to be enriched with upregulated proteins
(represented mostly by proteins in clusters 1 and 3). Proteins such as
ENO2, ALDOC, PGK1, and LDHA (Table 1) are involved in the glycolytic
pathway. Phosphofructokinase (PFK) catalyzes the conversion of
fructose 6-phosphate and ATP to fructose 1,6-biphosphate and ADP.
LDHA is another stable cytosolic enzyme that is very critical in the
conversion of pyruvate to lactate. The concentration of LDHA in hBMSCs
has nearly doubled at P7 as compared to P3. Higher concentration
of LDHA reduces the accumulation of pyruvate and thus reduces
the entry of pyruvate into oxidative metabolism. In effect, the up-
regulation of LDHA reduces the accumulation of oxidative stress
through the generation of mitochondrial ROS (Le et al., 2010). Further,
pyruvate kinase (PK) is among the highly expressed proteins in
hBMSCs and its expression increased by at least 1.5 fold at P7. PKcatalyzes the ﬁnal ATP-generation step in glycolysis. In tumor cells,
the inactive PK maintains the ﬂow of glycolytic intermediates into col-
lateral pathways for synthesis of nucleic acids, amino acids, and lipids
(Tamada et al., 2012). PK also plays roles during cell growth, prolifera-
tion and apoptosis; it senses nutritional scarcity (stress) during cell di-
vision and dissociates into an inactive form to protect cells from
nutritional stress-dependent apoptosis (Gupta and Bamezai, 2010).
Other enzymes such as aldolase C and phosphoglycerate mutase have
also been observed to increase in expression level with passage number.
From thepentose phosphate pathway, at least threeproteinswere upreg-
ulated at P7. Transldolase and aldolase C have shownmore than two-fold
increases as cells are cultured for extended periods. With regard to the
TCA cycle and pyruvatemetabolism, four proteins fromeachpathway ex-
perience an upward modulation pattern with in vitro culturing. Aldo-
keto reductase nearly quadrupled and the concentration of citrate syn-
thase increased by twofold.
3.4. Protein networks related to protein sorting, folding, and degradation
The protein networks in folding, sorting and degradation pro-
cesses (proteasome and endoplasmic) are primarily represented
by clusters C3, C5 and, C6. At P5 many endoplasmic reticulum (ER)
proteins were down-regulated. Such proteins include dolichyl
diphospho-oligosaccharide protein glycosyltransferase (OST48, average
fold change −2.1), heat shock protein 90 alpha (HS90A, −2.6×),
HS90B (−1.5×), HSP76 (−1.6×), protein disulﬁde isomerase A4
(PDIA4, −2.2×), and translocon-associated protein subunit delta
Fig. 3. Conﬁrmation of differential expression of proteins by two hBMSC cultures using ﬂow cytometry. The y-axes of the histograms show the mean ﬂuorescent intensity and it is
considered to be an estimate of the relative abundances of target proteins at P3 and P7. The differential expression proﬁles of galectin-1(4.4 fold) and proﬁlin-1 (1.8 fold) with in vitro
passaging were determined using LC-MSE. Using MS, we also determined the expression of CD135, CD247, and several others for which there was no prior evidence for expression on
hBMSCs (Mindaye et al., 2013a).
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Proteins whose concentration at P5 increased include calreticulin
(Calr, 1.5×), cytoskeletal associated protein 4 (CKAP4, 1.6×), heat
shock related 70 kDa protein (HSPA2, 1.5×), ribosome binding protein
1 (RRBP1, 1.7×), and various proteasomes including subunit alpha
type 1 (PSA1, 2.1×) (S1 in Mindaye et al., submitted for publication).
At P7, most of these proteins remain modulated as in the case of Calr
(2.6× compared to P3), HSP90AA1 (−1.7×), 60 kDa HSP (−1.7×),
protein disulﬁde isomerase (PDI, −1.5×), and SSR4 (−1.4×). The
ER lumen environment is considerably different from the cytosol and
thus favors several protein modiﬁcations (e.g., glycosylation and disul-
ﬁde bond formation). The ER protein processing system is controlled
by a specialized set of chaperons including glucose regulated protein
78 (GRP78, BiP), GRP94, folding enzymes like protein disulﬁde isomer-
ase, calnexin and calreticulin. The expression of BiP declines with age in
various animal models (Rabek et al., 2003). In hBMSCs, BiP expression
level decreased to close to 50% at P5 in three of the ﬁve cell cultures,
while the reduction in the other two samples was not signiﬁcant
(S1 in Ref. Mindaye et al., submitted for publication). BiP is a member
of the HSP70 family and its interaction with the hydrophobic domains
of most proteins hinders misfolding during translocation to the ER
(Naidoo, 2009). BiP is considered as the master regulator of ER stress
response signaling (Naidoo, 2009). Further, PDI and Calr are responsible
for the glycoprotein quality control system in cells (Naidoo, 2009). The
binding of Calr to proteins in ER allows foldases and disulﬁde isomerase
to catalyze the isomerization or exchange of disulﬁde bonds (Naidoo,2009). The expression level of PDI at P7 was 1.5 fold lower than P3,
while the content of Calr has increased by 2.5 fold (S1 in Ref. Mindaye
et al., submitted for publication). An age-associated decline in PDI
expression level has also been reported in numerous cases (Naidoo,
2009; Tomassini et al., 2004). Taken together, the alteration of key
regulators of the ER and proteasome protein processing systems
seems to suggest that there may be passage-associated disruption in
the protein folding and surveillance system in hBMSCs. Not surprisingly,
these protein processing systems are highly linked to multiple other
signaling functions and thus their alteration may initiate other
responses in cells. For example, the accumulation of aberrantly
folded proteins can trigger apoptotic signaling events, alteration of
cellular proliferation, or differentiation programs. It can also induce
secondary effects by altering the cell-matrix interactions or affecting
paracrine signaling (Tsang et al., 2010).
3.5. Proteins in the cell death and apoptotic signaling networks
Our analysis showed that proteins associated with the crucial func-
tions of proliferation and cell death including necrosis and apoptosis
were changed by extended cell culturing. When differentially regulated
proteins between P3 and P7 were compared using IPA Core analysis,
these cellular functions showed signiﬁcant changes: proliferation of
cells (p value 6.31E−8), cell death (3.58E−5), necrosis (4.42E−6),
and apoptosis (1.28E−4). Table 7 of S1 in Ref. Mindaye et al.
(submitted for publication) provides a summary of the differentially
Table 1
Differentially regulated proteins in the metabolic networks. A fold change is the ratio of
on-column quantity of proteins at P5 and P7 with respect to P3. An average fold-change
calculated using ﬁve cultures is shown.
ACCN Symbol Fold
(P5/P3)
Fold
(P7/P3)
Description
Glycolysis
P09972 ALDOC 3.3 2.8 Aldolase C, fructose-bisphosphate
P09104 ENO2 0.9 1.9 Enolase 2 (gamma, neuronal)
P00338 LDHA 1.6 1.9 Lactate dehydrogenase A
P18669 PGAM1 1.5 2.1 Phosphoglycerate mutase 1
P00558 PGK1 1.3 1.5 Phosphoglycerate kinase 1
P14618 PKM2 1.4 1.5 Pyruvate kinase, muscle
Pentose phosphate pathway
P37837 TALDO1 1.8 2.0 Transaldolase 1
O95336 PGLS 1.4 1.2 6-phosphogluconolactonase
P09972 ALDOC 3.3 2.8 Aldolase C, fructose-bisphosphate
Pyruvate metabolism
P15121 AKR1B1 1.7 3.6 Aldo-keto reductase family 1
P40925 MDH1 1.5 2.4 Malate dehydrogenase 1, NAD
P00338 LDHA 1.6 1.9 Lactate dehydrogenase A
P14618 PKM2 1.4 1.5 Pyruvate kinase, muscle
Citrate cycle (TCA cycle)
P53396 ACLY 1.3 1.3 ATP citrate lyase
Q99798 ACO2 1.2 2.1 Aconitase 2, mitochondrial
O75390 CS 1.7 2.0 Citrate synthase
P40925 MDH1 1.5 2.4 Malate dehydrogenase 1, NAD
Glyoxylate and dicarboxylate metabolism
P40925 MDH1 1.5 2.4 Malate dehydrogenase 1, NAD
Q99798 ACO2 1.2 2.1 Aconitase 2, mitochondrial
O75390 CS 1.7 2.0 Citrate synthase
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apoptosis, proliferation and death events in cells (IKDB). The depletion
of HSP27, HSP60, HSP70, and HSP90 has been shown to increase
sensitivity to apoptotic stimuli (Lanneau et al., 2008). HSP90 regulates
the activity and stability of apoptosis-implicated transcription factors
including NF-kB, p53, Akt, Raf-1, and JNK (Lanneau et al., 2008). The de-
pletion of only HSP70 in some cells stimulates a profound apoptotic re-
sponse through caspase-3 activation (Lanneau et al., 2008). In hBMSCs,
the expression of HSP70 and HSP90 was reduced by 50% or more
in most cultures. GAPDH is another pro-apoptotic protein whose ex-
pression level almost quadrupled at P7. Besides metabolic function,
GAPDH has roles in endocytosis, gene expression, tRNA transport, DNA
repair, and replication (Yi et al., 2010). Among the cathepsins family, ca-
thepsins B and D had higher expression levels at P7. These proteases
have cell context-dependent inﬂuence on apoptotic signaling. Cathepsin
Dmediates the release of cytochrome C into the cytosol and activation of
pro-caspase-3 and−9 (Liaudet-Coopman et al., 2006). In cancer cells,
cathepsins have anti-apoptotic roles (Liaudet-Coopman et al., 2006).
Among the negative regulators of apoptosis, FHL-2 has themost fold
change (3.1 fold increase). Studies have shown that FHL2 protects liver
cells from doxorubicin-induced damage (Ng et al., 2011). Peroxiredoxin
6 (2.5 fold higher at P7) protects cells from apoptosis either through de-
toxifying ROS or interactingwith caspase-8 and−10 (Choi et al., 2011).
Gelsolin has both pro and anti-apoptotic roles depending on cell type
and experimental conditions. In neutrophils, gelsolin is a substrate for
caspase-3 and its cleavage facilitates the severing of actin ﬁlaments
resulting in the dismantling of the membrane cytoskeleton, which is
the hallmark of apoptosis. On the other hand, the intact gelsolin
can interact with mitochondrial VDAC to inhibit the release of cyto-
chrome C and subsequent apoptotic cascades (Leifeld et al., 2006).
The expression of gelsolin and VDAC in hBMSCs increases by 2.5
and 2.3 fold, respectively. Furthermore, the level of superoxide dismut-
ase (SOD) increases by almost 70% at P7 and this enzyme is known to
block the activation of caspase cascade in response to apoptotic stimuli
(Dimmeler et al., 1999).3.6. Proteins in the growth and proliferation signaling networks
The proteomic networks related to cell growth and proliferation
have also been altered signiﬁcantly with passaging (see Table 7 of S1
in Ref. Mindaye et al., submitted for publication). For example, galectin
1 had higher expression level at P7. Galectin 1 interacts with α5β1
integrin, induces p21 transcription, and stabilizes p27, which results in
G1 cell cycle arrest and growth inhibition (Camby et al., 2006). Galectin
1 role in hBMSC is to suppress the proliferation of T cells (Gieseke et al.,
2010). Proﬁlin is another ubiquitously expressed actin-binding protein
whose expression in hBMSCs nearly doubles at P7. Reports show
that proﬁlin has an anti-proliferative effect partly by increasing the ex-
pression of CDK inhibitors (e.g., p27, kip 1) (Zou et al., 2010). Among
the annexins, ANXA1, ANXA2, and ANXA5 have at least twice the
protein levels by P7. While ANXA1 has a cell-type independent anti-
proliferative action through sustained activation of ERK signaling
cascade (Alldridge and Bryant, 2003), ANXA2 has a pro-proliferative
role in human HeLa 293 cells (Chiang et al., 1999). Similarly, the level
of four and a half LIM domain-containing proteins (FHL1 and FHL2)
was signiﬁcantly altered with passaging, where the content of FHL1
increased fourfold and FHL2 threefold. FHLs, through protein-protein
interactions, inﬂuence apoptotic signaling and proliferation in a cell-
dependent manner (Ding et al., 2009). In ﬁbroblasts, FHL2 activates
cyclin 1 and plays a positive role in cell proliferation; in tumor cells,
the increased FHL2 expression inhibits proliferation by decreasing
cyclin D1 content while increasing p21 expression (Labalette et al.,
2008; Ng et al., 2011). In BMSCs, FHL2 control the osteogenic differen-
tiation and bone formation through modulation of Wnt molecules
(Brun et al., 2013).
3.7. Conﬁrmation of expression changes using ﬂow cytometry
To further conﬁrm the expression changes detected using label-free
MSE technique, independent experiments using ﬂow cytometry in con-
junction with polyclonal antibodies were run for galectin 1 and proﬁlin
using samples 167696 and PCBM1662 at P3 and P7. The measurements
determined the populations of cells that express target proteins and
helped estimate the protein abundances at P7 in relation to P3 (Fig. 2).
Furthermore, we previously reported the expression of at least 14 new
CDs for which there was no prior evidence of expression on hBMSCs
(Mindaye et al., 2013a). To provide more evidence of their expression
and study their expression changes in relation to cell passaging, we
also included three CDs (CD135, CD243, and CD247) in these ﬂow
cytometry experiments. Fig. 2 summarizes the relative expressions of
target proteins at P3 in relation to P7. Themean ﬂuorescence intensities
were used to estimate the relative expression levels. Conformingly, the
expression changes based on ﬂow cytometry and label-free MS tech-
nique follows similar trends although the changes determined using
ﬂow measurements are slightly lower than those obtained using
LC-MSE approach. For example, galectin 1 increases by at least fourfold
based on MS data but an average of 1.4 fold increase (1.3× for
PCBM1662 and 1.4× for 167696) was determined using ﬂow cytometry.
4. Discussion
Aging-associated phenotype change in hBMSCs is one of the most
important considerations in furthering the advancement of cell-based
therapy and is a subject of numerous studies and reviews (Baker et al.,
2015; Bara et al., 2014). In regard to the in vivo aging, there is a general
agreement between most studies in that the cell ﬁtness declines with
aging. For example, with age of the bone marrow the frequency of
CFUs declines, susceptibility to senescence increase, and cells have re-
duced migration and adhesion capacity (Baker et al., 2015). The clinical
performance of BMSCs from aged individuals has also been shown in
most instances to be less than cells from younger counterparts (Baker
et al., 2015). In vitro aging is also very critical in inﬂuencing therapy
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requires extensive in vitro expansion of cells. In vitro culturing exposes
cells to numerous artiﬁcial stresses. For example, harvesting cells
using enzymatic treatment (usually trypsin, collagenase, accutase, or
mixture of them) exposes cells to a condition where the surface
proteins could be partially cleaved and this may initiate a cascade of bi-
ological events (Huang et al., 2010). The effect of in vitro passaging on
hBMSC's phenotype has been examined in numerous occasions
(Bruder et al., 1997; Lo Surdo and Bauer, 2012; Lo Surdo et al., 2013;
Wagner et al., 2010). We also observed, among others, that metabolic
pathways are largely altered, where many proteins in the glycolytic,
pentose phosphate, and TCA pathwayswere shown to be largely upreg-
ulated in late passages. An expression trend similar to ours for some of
the proteins has already been reported by other authors. Using 2D gel
techniques, Sun and coworkers showed the expression levels of pyru-
vate kinase and enolase increase with serial sub-culturing of hBMSCs
(Sun et al., 2006). In a separate report, Madeira et al. used a comparable
technique to report similar induction of GAPDH, aldolase, and aldo-keto
reductase with in vitro aging of cells (Madeira et al., 2012).
Proteins in the metabolic networks are traditionally considered to
have housekeeping functions, although this notion has recently evolved
as they are recognized to play vital roles in proliferation, self-renewal,
differentiation, and aging (Shyh-Chang et al., 2013). For example,
hiPSCs experience a high glycolytic ﬂux during oxidative stress. During
differentiation of hiPSCs, genes in the pentose phosphate and lipid
biosynthesis pathways become upregulated (Zhang et al., 2012).
Further, one of the changes during reprograming of somatic cells
is the progressive increase in glycolytic genes. In fact, the metabolic
network is claimed to be the major barrier during reprograming
(Hansson et al., 2012; Zhang et al., 2012). The metabolic network has
also been shown to play important roles in hBMSC biology. Glycolysis
is the major source of energy during chondrogenic differentiation and
hypoxia suppresses osteogenic differentiation of hBMSCs (Pattappa
et al., 2011). In regards to self-renewal and expansion, some reports
have already indicated that the underlying metabolic pathways have
a signiﬁcant effect on population doublings, frequency of primitive
cells in a colony, colony size, and number of colonies in culture media
(Estrada et al., 2012; Pattappa et al., 2011; Sanchez-Arago et al., 2013).
BMSCs retain the ﬂexibility to use both oxidative phosphorylation and
glycolytic pathways (Pattappa et al., 2011; Schop et al., 2009). Under
normoxic conditions, non-differentiating BMSCs depend more on
glycolysis (~70%) and part of the reason may be that cells require not
just ATP, but also other metabolic byproducts. Besides, glycolysis
protects cells from excessive generation of ROS, the primary cause of
cellular damage and senescence (Pattappa et al., 2011; Shyh-Chang
et al., 2013). The fact that enzyme content in the glycolytic network
increased with passage seems to indicate that glycolytic pathway
may be preferred even more so as hBMSCs are subjected to stress
caused by long-term passaging. Interestingly, gene expression assays
in BMSCs also pointed to similar bioenergetic alteration trendswithpas-
saging (Will, 2010). Therefore, as we seek to gain clearer understanding
of the relationship between metabolic networks and some key features
of hBMSCs; the differentially regulated metabolic enzymes identiﬁed in
this study may be key starting targets.
We also observed the alteration of proteomic networks related to
the apoptotic and proliferative pathways. Senescence and apoptosis
are essential mechanisms for cells to respond to the changing environ-
ment. Apoptosis involves intricate proteomic networks and Table 7 of
S1 in Ref. Mindaye et al., (submitted for publication) summarizes
modulated proteins in hBMSCs that are linked in prior studies with ap-
optosis (IKDB). Some of these are pro- and others are anti-apoptotic
proteins. Stress-related heat shock proteins have been markedly re-
duced at P7, observations consistent with expectations (Madeira et al.,
2012). GAPDH is another important pro-apoptotic protein whose ex-
pression level almost quadrupled at P7. During apoptosis, its expression
and mitochondrial accumulation increases and this leads to increasedmembrane permeability with subsequent release of pro-apoptotic pro-
teins (Tarze et al., 2007). Based on systematic IPA analysis, apoptosis has
an overall activation z score of 1.6 (the fold change that this biological
function increased at P7 as compared to P3). Other cellular events
with similar biological tendencies are cell death and necrosis, each
with activation z-scores of 2.1 and 1.8, respectively. Moreover, proteins
involved in cell growth and proliferation have also experienced
passage-dependent expression patterns (p value 6.31E−8). The
overall decline in proliferation capacity has−0.60 z-score, indicating
P7 cells become somewhat less proliferative than P3. These results
correlate with the signiﬁcant reduction in the frequency of CFUs or
increase in time to 80% conﬂuence of all hBMSC sampleswith passaging
except 8F3560, which had fairly constant CFUs across passaging (Lo
Surdo et al., 2013). According to the IKDB, some of the proliferation-
associated proteins are pro-proliferative (e.g., nucleolin); however,
most are anti-proliferative (e.g., galectin 1 and annexin 1), and the
effect on proliferation for some proteins is cell context-dependent
(e.g., annexin 2).
Taken together, hBMSC-based therapy and research depend highly
on the isolation and manufacturing of cells with predictable biological
functions in large numbers. We extensively explored the underpinning
molecular factors that inﬂuence the age-associated phenotype changes
in hBMSCs. Using a robust label-free quantitative proteomic approach,
the study mapped the expression changes associated with long-term
passaging in ﬁve hBMSC cultures derived from different human donors.
Over 1700 proteinswere quantiﬁed at three passages and a differential-
ly expressed protein list was identiﬁed. Bioinformatic-based network
analysis and term enrichment helped to identify altered biological
functions. We documented that culturing stimulates extensive proteo-
mic alterations in functional categories including apoptosis, ER-based
protein processing and sorting, and metabolic pathways. Identiﬁcation
of these affected biological functions together with the underlying
molecular networks tremendously beneﬁt the effort to uncovering
targets that are not just used to monitor cell ﬁtness but that can
also be employed to slowdown the in vitro aging process in hBMSCs
and hence ensure manufacturing of cells with known quality, efﬁcacy
and stability.
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